Journal of mucopolysaccharidosis and rare diseases

Association for Research of MPS and Rare Diseases (뮤코다당증연구학회)
권호 표지
DOI QR코드

DOI QR Code

The Role of Enzyme Replacement Therapy in Fabry Disease in Cardiology Perspective

  • Hongo, Kenichi (Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine)
  • Received : 2018.05.31
  • Accepted : 2018.06.11
  • Published : 2018.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Fabry disease is a hereditary lysosomal storage disorder caused by the reduction or absence of lysosomal enzyme alpha-galactosidase A and the accumulation of glycosphingolipids, such as globotriaosylceramide (Gb3), in various organs, including the heart. The prevention of cardiac involvement in Fabry disease can only be achieved by enzyme replacement therapy (ERT), and the method of assessing the efficacy of ERT should be confirmed. Changes in the electrocardiogram, such as the shortening of PQ interval, prolongation of QTc and repolarization abnormalities as well as left ventricular hypertrophy in voltage criteria, can be used to identify Fabry disease patients; however, the usefulness of electrocardiograms for evaluating the efficacy of ERT is limited. The assessment of left ventricular hypertrophy using echocardiography has been established to evaluate the efficacy of ERT during long-term period. A new technique involving speckled tracking method might be useful for detecting early cardiac dysfunction and identifying the effect of ERT for a relatively short period. The estimation of left ventricular hypertrophy using cardiac magnetic resonance (CMR) is also useful for assessing the efficacy of ERT. Identifying late gadolinium enhancement in CMR may affect the effectiveness of ERT, and the new technique of T1 mapping might be useful for monitoring the accumulation of Gb3 during ERT. Histopathology in cardiac biopsy specimens is another potentially useful method for identifying the accumulation of GB3; however, the use of histopathology to evaluate of the efficacy of ERT is limited because of the invasive nature of an endomyocardial biopsy.

Keywords

References

  1. Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539-48. https://doi.org/10.1097/01.gim.0000237866.70357.c6
  2. Kobayashi M, Ohashi T, Sakuma M, Ida H, Eto Y. Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease. J Inherit Metab Dis 2008;31 Suppl 3:483-7. https://doi.org/10.1007/s10545-007-0740-6
  3. Eto Y, Ohashi T, Utsunomiya Y, Fujiwara M, Mizuno A, Inui K, et al. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. J Inherit Metab Dis 2005;28:575-83. https://doi.org/10.1007/s10545-005-0575-y
  4. Talbot AS, Lewis NT, Nicholls KM. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease. Heart 2015:101:287-93. https://doi.org/10.1136/heartjnl-2014-306278
  5. Seydelmann N, Wanner C, Störk S, Ertl G, Weidemann F. Fabry disease and the heart. Best Pract Res Clin Endocrinol Metab 2015;29:195-204. https://doi.org/10.1016/j.beem.2014.10.003
  6. Kono Y, Wakabayashi T, Kobayashi M, Ohashi T, Eto Y, Ida H, et al. Characteristics of cerebral microbleeds in patients with Fabry disease. J Stroke Cerebrovasc Dis 2016;25:1320-5. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.02.019
  7. Putko BN, Wen K, Thompson RB, Mullen J, Shanks M, Yogasundaram H, et al. Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment. Heart Fail Rev 2015;20:179-91. https://doi.org/10.1007/s10741-014-9452-9
  8. Namdar M. Electrocardiographic changes and arrhythmia in Fabry disease. Front Cardiovasc Med 2016;3:7.
  9. Frustaci A, Morgante E, Russo MA, Scopelliti F, Grande C, Verardo R, et al. Pathology and function of conduction tissue in Fabry disease cardiomyopathy. Circ Arrhythm Electrophysiol 2015;8:799-805. https://doi.org/10.1161/CIRCEP.114.002569
  10. Senechal M, Germain DP. Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin Genet 2003;63:46-52.
  11. Namdar M, Kampmann C, Steffel J, Walder D, Holzmeister J, Lüscher TF, et al. PQ interval in patients with Fabry disease. Am J Cardiol 2010;105:753-6. https://doi.org/10.1016/j.amjcard.2009.10.056
  12. Namdar M, Steffel J, Jetzer S, Schmied C, Hürlimann D, Camici GG, et al. Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease. Am J Cardiol 2012;109:587-93. https://doi.org/10.1016/j.amjcard.2011.09.052
  13. Bacharova L, Estes EH. Left ventricular hypertrophy by the surface ECG. J Electrocardiol 2017;50:906-8. https://doi.org/10.1016/j.jelectrocard.2017.06.006
  14. Motwani M, Banypersad S, Woolfson P, Waldek S. Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol Genet Metab 2012;107:197-202. https://doi.org/10.1016/j.ymgme.2012.05.011
  15. Madsen CV, Bundgaard H, Rasmussen AK, Sorensen SS, Petersen JH, Kober L, et al. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study. Scand Cardiovasc J 2017;51:207-16. https://doi.org/10.1080/14017431.2017.1332383
  16. Engelen MA, Brand E, Baumeister TB, Marquardt T, Duning T, Osada N, et al. Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data. BMJ Open 2012;2:e000879.
  17. Schmied C, Nowak A, Gruner C, Olinger E, Debaix H, Brauchlin A, et al. The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy. Heart 2016;102:1309-14. https://doi.org/10.1136/heartjnl-2015-308897
  18. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudova J, Karetova D, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000;139:1101-8. https://doi.org/10.1067/mhj.2000.105105
  19. Kampmann C, Linhart A, Baehner F, Palecek T, Wiethoff CM, Miebach E, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 2008;130:367-73. https://doi.org/10.1016/j.ijcard.2008.03.007
  20. Hongo K, Ito K, Date T, Anan I, Inoue Y, Morimoto S, et al. The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patients. Mol Genet Metab 2008, in press.
  21. Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci MV, Procaccini D, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 2004;66:158-65. https://doi.org/10.1111/j.1399-0004.2004.00284.x
  22. Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment. Orphanet J Rare Dis 2015;10:125. https://doi.org/10.1186/s13023-015-0338-2
  23. Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 2015;52:353-8. https://doi.org/10.1136/jmedgenet-2014-102797
  24. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108:1299-301. https://doi.org/10.1161/01.CIR.0000091253.71282.04
  25. Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, et al. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective longterm cardiac magnetic resonance imaging study. Heart 2009;95:1103-7. https://doi.org/10.1136/hrt.2008.162800
  26. Collin C, Briet M, Tran TC, Beaussier H, Benistan K, Bensalah M, et al. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease. Eur J Prev Cardiol 2012;19:43-54. https://doi.org/10.1177/1741826710391118
  27. Nojiri A, Hongo K, Kawai M, Komukai K, Sakuma T, Taniguchi I, et al. Scoring of late gadolinium enhancement in cardiac magnetic resonance imaging can predict cardiac events in patients with hypertrophic cardiomyopathy. J Cardiol 2011;58:253-60. https://doi.org/10.1016/j.jjcc.2011.07.007
  28. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005;26:1461-74. https://doi.org/10.1093/eurheartj/ehi258
  29. Kozor R, Grieve SM, Tchan MC, Callaghan F, Hamilton-Craig C, Denaro C, et al. Cardiac involvement in genotypepositive Fabry disease patients assessed by cardiovascular MR. Heart 2016;102:298-302. https://doi.org/10.1136/heartjnl-2015-308494
  30. Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 2011;4:592-601. https://doi.org/10.1016/j.jcmg.2011.01.020
  31. Hsu TR, Hung SC, Chang FP, Yu WC, Sung SH, Hsu CL, et al. Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation. J Am Coll Cardiol 2016;68:2554-63. https://doi.org/10.1016/j.jacc.2016.09.943
  32. Weidemann F, Sanchez-Nino MD, Politei J, Oliveira JP, Wanner C, Warnock DG, et al. Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis 2013;8:116. https://doi.org/10.1186/1750-1172-8-116
  33. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013;6:392-8. https://doi.org/10.1161/CIRCIMAGING.112.000070
  34. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:2888-93.
  35. Kobayashi M, Ohashi T, Fukuda T, Yanagisawa T, Inomata T, Nagaoka T, et al. No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the ${\alpha}$-galactosidase A gene. Mol Genet Metab 2012;107:711-5. https://doi.org/10.1016/j.ymgme.2012.10.018
  36. Hsu TR, Sung SH, Chang FP, Yang CF, Liu HC, Lin HY, et al. Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A). Orphanet J Rare Dis 2014;9:96. https://doi.org/10.1186/1750-1172-9-96
  37. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 2007;50:1914-31. https://doi.org/10.1016/j.jacc.2007.09.008
  38. Najafian B, Tondel C, Svarstad E, Sokolovkiy A, Smith K, Mauer M. One year of enzyme replacement therapy reduces globotriaosylceramide inclusions in podocytes in male adult patients with Fabry disease. PLoS One 2016;11:e0152812. https://doi.org/10.1371/journal.pone.0152812
  39. Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan MW. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 2009;119:2561-7. https://doi.org/10.1161/CIRCULATIONAHA.108.841494